Visualization and hotspot analysis of CAR-T research based on CiteSpace

Abstract

Through bibliometric analysis of CAR-T research hotspots and development trends, a reference is provided to promote cutting-edge research on CAR-T. Acquired research literature on CAR-T cells from the Web of Science Core Collection (WOSCC) as of November 20, 2023, and utilized CiteSpace software to conduct bibliometric and knowledge graph analysis. A total of 3664 articles of valid literature were obtained between 1996 and 2023. The number of publications grew slowly from 1996 to 2014 and increased sharply from 2015. In particular, from 2018 to 2022, the number of publications showed explosive growth and remained at a high level. The authors of the papers are relatively scattered, and there is little cooperation between authors. The United States has published the most papers in this field and has close cooperation with global research institutions, while China ranks second in terms of the number of papers published and has less academic cooperation or exchanges with other countries/regions. The main research hotspots include chimeric antigen receptor, immunotherapy, cytokine release syndrome, etc., which belong to two categories: the treatment mechanism and application of CAR-T and adverse reactions and safety management. Keyword mutation analysis predicts that future research hotspots will mainly be related to technical research, safety, and post-treatment management of CAR-T. CAR-T is a hot research field and is still in a rapid development stage. Domestic researchers need to strengthen exchanges and cooperation with international researchers. CAR-T-related technical research, safety, and post-treatment management may be the hot spots of future research.

Keywords

CAR-T / CiteSpace / hotspot analysis

References

[1] Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4): 69.

[2] Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in universal CAR-T cell therapy. Front Immunol. 2021; 12: 744823.

[3] Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-cell persistence. Int J Mol Sci. 2021; 22(19): 10828.

[4] Schubert M-L, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021; 32(1): 34-48.

[5] Zheng Y, Nandakumar KS, Cheng K. Optimization of CAR-T cell-based therapies using small-molecule-based safety switches. J Med Chem. 2021; 64(14): 9577-9591.

[6] Leung WK, Ayanambakkam A, Heslop HE, Hill LC. Beyond CD19 CAR-T cells in lymphoma. Curr Opin Immunol. 2022; 74: 46-52.

[7] Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021; 18(5): 1085-1095.

[8] Roselli E, Faramand R, Davila ML. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. J Clin Invest. 2021; 131(2): e142030.

[9] Fiorenza S, Turtle CJ. CAR-T cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success. BioDrugs. 2021; 35(3): 281-302.

[10] Zhong D, Li Y, Huang Y, Hong X, Li J, Jin R. Molecular mechanisms of exercise on cancer: a bibliometrics study and visualization analysis via CiteSpace. Front Mol Biosci. 2022; 8: 797902.

[11] Liu S, Sun Y-P, Gao X-L, Sui Y. Knowledge domain and emerging trends in Alzheimer's disease: a scientometric review based on CiteSpace analysis. Neural Regen Res. 2019; 14(9): 1643-1650.

[12] Shi Y, Luo J, Wang X, et al. Emerging trends on the correlation between neurotransmitters and tumor progression in the last 20 years: a bibliometric analysis via CiteSpace. Front Oncol. 2022; 12: 800499.

[13] Wu N, Li M. A CiteSpace-based analysis of the development trends affecting clinical research nurses in China: a systematic review. J Multidiscip Healthc. 2022; 15: 2363-2374.

[14] Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16): 1509-1518.

[15] Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16): 1507-1517.

[16] Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C-x, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022; 41(1): 119.

[17] Wei J, Guo Y, Wang Y, et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021; 18(4): 792-804.

[18] Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013; 3(4): 388-398.

[19] Maalej KM, Merhi M, Inchakalody VP, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023; 22(1): 20.

[20] Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023; 402(10416): 2034-2044.

RIGHTS & PERMISSIONS

2025 The Author(s). Precision Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital.